[DOI] [PubMed] [Google Scholar] 62.Judk P, Esposito S, Coppieters G, Van Eenoo P, Deventer K
Wang et al., 2024)
And remember, this result came from the shorter trial
Consumers should verify current regulatory status before purchasing
For obesity treatment, dose escalation protocols starting at lower doses (e.g., 2 mg) and gradually increasing to maintenance doses (e.g., 4 mg, 8 mg, or 12 mg) have been studied Link below for more detailed information: Product Overview: Retatru/Cagrilintide is a dual-compound research peptide combining Retatru, a novel multi-agonist peptide with activity across GLP-1, GIP, and glucagon pathways, and Cagrilintide, an amylin analog